Drug companies, health technology assessment bodies, ethicists and patient groups are among the raft of stakeholders that can now have their say on the multi-stakeholder platform (MSP) that EU regulators want to set up this year to enable discussions on improving Europe’s clinical trials landscape.
The MSP’s establishment is described in a concept paper that the European Medicines Agency, the EU’s Heads of Medicines Agencies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?